A new weapon in the fight against osteoarthritis?
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating osteoarthritis. This is based on a polysaccharide, a long-chain sugar molecule, originating from brown algae. When chemically modified, this “alginate” reduces oxidative stress, has an anti-inflammatory effect in cell culture tests and suppresses the immune reaction against cartilage cells, thereby combating the causes of arthritis. The research is, however, still in its infancy.
Osteoarthritis is the most-widespread joint disease, with around 90 percent of all people over 65 being affected to varying degrees, but this degenerative disease is also widespread amongst younger people. In arthritis, the cartilage in the joint, a type of protective layer on bones that “lubricates” the joint, degenerates over time. This can be extremely painful for sufferers, because inflammatory reactions are associated with cartilage degeneration. In the later stages of the disease, bones are no longer adequately protected and can directly rub against each other.
Osteoarthritis can affect all joints in the body, but most often affects the knee joint, hip joint and fingers. The disease has been considered incurable until now. Current treatment methods, such as anti-inflammatory drugs and painkillers, mainly address the symptoms. Often, the only remaining option is an operation to replace the affected joint with an artificial one.
Initial research results are encouraging
In laboratory tests, the team led by ETH researcher Marcy Zenobi-Wong and Empa researcher Katharina Maniura has now succeeded, together with SINTEF in Norway, in identifying a substance with the potential to halt cartilage degeneration in joints. This substance is the polysaccharide alginate extracted from the stems of brown algae – or more precisely cuvie (Lat. Laminaria hyperborea), which is similar to specific extracellular biomolecules in cartilage. The researchers chemically modified the alginate with sulfate groups and then added it in dissolved form to cell cultures to examine the reaction of various cell types to the modified polysaccharide. This revealed that alginate sulfate can significantly reduce oxidative stress, which is a frequent cause of cell damage or even cell death, and the more sulfate groups attached to the alginate molecule, the greater this reduction.
Alginate sulfate was also able to suppress the inflammatory reaction, again depending on the number of sulfate groups, and was able to down-regulate the expression of genes that trigger an inflammatory reaction in both human cartilage cells, known as chondrocytes, and in macrophages, the “scavenger cells” of our immune system. The algal molecules should therefore slow down cartilage degeneration. “The hope is that they can even stop this degeneration,” says Empa researcher Markus Rottmar.
Further research work necessary
The alginate sulfates have so far only been tested in vitro, i.e. in the laboratory with cell cultures. However, the encouraging results mean that research will now continue. The next stage is to test the substances on animals. If this is also successful, clinical trials can then be conducted on people. These tests are, however, laborious and time-consuming. If everything were to work perfectly, it would still be a few years before arthritis patients could be treated with alginate sulfate.
Learn more: Treating arthritis with algae
The Latest on: Osteoarthritis
- Synthetic joint lubricant holds promise for osteoarthritis on June 19, 2019 at 12:53 pm
A new type of treatment for osteoarthritis, currently in canine clinical trials, shows promise for eventual use in humans. The treatment, developed by Cornell University biomedical engineers, is a ... […]
- Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial Nasdaq:SRNE on June 19, 2019 at 5:10 am
(MENAFN - GlobeNewsWire - Nasdaq) itemprop="articleBody"> Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight ... […]
- Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis on June 19, 2019 at 5:00 am
SAN DIEGO, June 19, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has dosed the first patient in its Phase 3 STRIDES-X-ray trial of lorecivivint (SM04690), a CLK/DYRK inhibitor ... […]
- Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial on June 19, 2019 at 4:00 am
Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group). ... […]
- UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee Nasdaq:UBX on June 18, 2019 at 5:20 am
SAN FRANCISCO, June18, 2019(GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or ... […]
- Early Intervention in Osteoarthritis Has Potential to Help Control Pain and Disability, Reduce Work Loss on June 14, 2019 at 10:15 pm
Osteoarthritis (OA) is highly prevalent and yet there is no cure for it. We all know that nonpharmacologic management, including exercise and weight loss, is the fundamental of treatment in early OA. ... […]
- 14 foods that support the treatment of osteoarthritis most effectively on June 14, 2019 at 9:22 pm
Joint pain is a common symptom that occurs when we are physically active or injured. There are many ways to overcome joint pain, but it will be very effective if you know how to combine them with ... […]
- Galapagos Ends Enrollment in Osteoarthritis Study Before Time on June 12, 2019 at 4:21 pm
Galapagos NV GLPG announced that it has completed patient recruitment in the phase II study on its pipeline candidate, GLPG1972/S201086, for the treatment of osteoarthritis (OA). The company ... […]
- Low-Dose Steroid Reduces Hand Pain in Osteoarthritis on June 12, 2019 at 1:04 pm
MADRID -- Patients diagnosed with osteoarthritis that causes hand and finger pain got relief with low-dose prednisolone, according to a study reported here at the annual European Congress of ... […]
- Low-dose prednisolone significantly improves pain symptoms and function in hand osteoarthritis on June 12, 2019 at 12:16 am
The results of the low-dose prednisolone in patients with hand osteoarthritis (HOPE) study presented today at the Annual European Congress of Rheumatology (EULAR 2019) show that low-dose ... […]
via Google News and Bing News